A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Belinostat (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Anaplastic large cell lymphoma; B cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- 13 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2020.
- 13 Apr 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.